The long-term safety of genetically modified T cells for therapeutic applications remains a crucial concern. A comprehensive analysis of 783 patients across multiple clinical trials, with >2,200 patient-years of follow-up, found no strong evidence linking these therapies to insertional oncogenesis.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Learn more
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: Enrichment and depletion of genes at CAR-vector integration sites.
References
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018). A review on T cell engineering for durable remissions and associated toxicities.
ArticlePubMedPubMed CentralCASGoogle Scholar
Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255–256 (2003). This paper reports sustained correction of an inherited immunodeficiency by ex vivo retroviral gene transfer in multiple patients, but also a case of malignant T cell proliferation from vector integration.
ArticlePubMedGoogle Scholar
Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Investig. 118, 3143–3150 (2008). This paper reports leukemogenesis in patients treated with gammaretroviral gene therapy, highlighting the toxicity of viral enhancer elements.
ArticlePubMedPubMed CentralCASGoogle Scholar
Verdun, N. & Marks, P. Secondary cancers after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 390, 584–586 (2024). A review summarizing 22 reported cases of T cell cancers after CAR-T cell therapy.
ArticlePubMedCASGoogle Scholar
Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in. TP53. N. Engl. J. Med. 392, 577–583 (2025).
ArticlePubMedCASGoogle Scholar
Dulery, R. et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat Med.https://doi.org/10.1038/s41591-024-03458-w (2025). References 5 and 6 report T cell malignancies following CAR-T cell therapy.
ArticlePubMedGoogle Scholar
Download references
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Jadlowsky, J. K. et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat. Med. https://doi.org/10.1038/s41591-024-03478-6 (2025).
Rights and permissions
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Assessing the risks of engineered T cells. Nat Med (2025). https://doi.org/10.1038/s41591-025-03598-7
Download citation
Published:10 March 2025
DOI:https://doi.org/10.1038/s41591-025-03598-7
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative